[Form 3/A] Skye Bioscience, Inc. Amended Initial Statement of Beneficial Ownership
Rhea-AI Filing Summary
Skye Bioscience Chief Operating Officer Diep Tuan Tu filed an amended insider ownership report to add previously omitted equity awards. The filing lists restricted stock unit awards for up to 72,833 shares that vest in stages when Skye’s market capitalization reaches $125M, $250M, $400M and at an exit of $500M or greater, with acceleration upon a change in control. It also details an additional RSU grant vesting in three equal annual installments from December 14, 2021. Several stock option grants are disclosed, including options over 8,000 shares at an exercise price of $11.25 expiring in 2030, and options over 7,080, 22,021 and 9,194 shares at $3.50–$14.50 per share expiring between 2031 and 2033, all subject to service-based vesting and full vesting on a change in control.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The restricted stock unit ("RSU") award was omitted from the Reporting Person's original Form 3, filed on March 4, 2024. Represents RSU awards for up to 72,833 shares that vest on the following performance milestones: 25% vests upon achieving a market cap of $125M, an additional 25% vests upon achieving a market cap of $250M, an additional 25% vests upon achieving a market cap of $400M, an additional 25% vest at an exit of $500M or greater; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs . Upon a change in control of the Issuer, 100% of the RSUs will become fully vested. The restricted stock unit ("RSU") award was omitted from the Reporting Person's original Form 3, filed on March 4, 2024. Represents a RSU award that vests in three equal annual installments commencing on the first anniversary of the grant date, December 14, 2021 Upon a change in control of the Issuer, all of the RSUs will vest in full. The stock option was omitted from the Reporting Person's original Form 3, filed on March 4, 2024. The stock option vests 10% on the grant date, October 5, 2020, and the remaining 90% of the stock option will vest in equal semi-annual installments over four annual periods. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. The stock option was omitted from the Reporting Person's original Form 3, filed on March 4, 2024. The stock option vests 25% on the one year anniversary of the grant date, December 14, 2021, and 1/48th monthly thereafter. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. The stock option was omitted from the Reporting Person's original Form 3, filed on March 4, 2024. The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is August 25, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. The stock option was omitted from the Reporting Person's original Form 3, filed on March 4, 2024. The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is November 6, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested.